Why NeoGenomics (NEO) Stock Is Up Today

NEW YORK (TheStreet) -- NeoGenomics (NEO) was gaining 18.7% to $5.20 Thursday after beating analysts' expectations for revenue in the second quarter.

For the second quarter NeoGenomics reported earnings of 2 cent a share, in line with the Capital IQ Consensus Estimate. Revenue grew 32.7% from the year-ago quarter to $20.7 million, above analysts' estimates of $20.12 million.

Looking to the third quarter NeoGenomics expects earnings of between a loss of 1 cent and a 1 cent a share while analysts expect the company to break even for the quarter. The company expects revenue of $22 million to $23.5 million in the third quarter, about analysts' expectations of $21.6 million.

Must read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NEO ChartNEO data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

General Electric Booted From Dow, Replaced by Walgreens

General Electric Booted From Dow, Replaced by Walgreens